CN105992762B - 制造嘧啶磺酰胺衍生物的方法 - Google Patents
制造嘧啶磺酰胺衍生物的方法 Download PDFInfo
- Publication number
- CN105992762B CN105992762B CN201580008410.3A CN201580008410A CN105992762B CN 105992762 B CN105992762 B CN 105992762B CN 201580008410 A CN201580008410 A CN 201580008410A CN 105992762 B CN105992762 B CN 105992762B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- formulas
- salt
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710130956.7A CN107162988B (zh) | 2014-02-14 | 2015-02-13 | 制造嘧啶磺酰胺衍生物的方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14155137.4 | 2014-02-14 | ||
| EP14155137.4A EP2907811A1 (en) | 2014-02-14 | 2014-02-14 | Process for manufacturing pyrimidine sulfamide derivatives |
| PCT/EP2015/053047 WO2015121397A1 (en) | 2014-02-14 | 2015-02-13 | Process for manufacturing pyrimidine sulfamide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710130956.7A Division CN107162988B (zh) | 2014-02-14 | 2015-02-13 | 制造嘧啶磺酰胺衍生物的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105992762A CN105992762A (zh) | 2016-10-05 |
| CN105992762B true CN105992762B (zh) | 2019-04-16 |
Family
ID=50073084
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710130956.7A Active CN107162988B (zh) | 2014-02-14 | 2015-02-13 | 制造嘧啶磺酰胺衍生物的方法 |
| CN201580008410.3A Active CN105992762B (zh) | 2014-02-14 | 2015-02-13 | 制造嘧啶磺酰胺衍生物的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710130956.7A Active CN107162988B (zh) | 2014-02-14 | 2015-02-13 | 制造嘧啶磺酰胺衍生物的方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9938244B2 (enExample) |
| EP (3) | EP2907811A1 (enExample) |
| JP (2) | JP6431922B2 (enExample) |
| KR (2) | KR102406358B1 (enExample) |
| CN (2) | CN107162988B (enExample) |
| AR (2) | AR099434A1 (enExample) |
| AU (2) | AU2015217000B2 (enExample) |
| BR (2) | BR112016018581B1 (enExample) |
| CA (1) | CA2937277C (enExample) |
| CL (2) | CL2016002008A1 (enExample) |
| CY (1) | CY1123319T1 (enExample) |
| DK (1) | DK3105220T3 (enExample) |
| EA (2) | EA032933B1 (enExample) |
| ES (2) | ES2819504T3 (enExample) |
| HK (1) | HK1243405A1 (enExample) |
| HR (1) | HRP20201450T1 (enExample) |
| HU (1) | HUE050974T2 (enExample) |
| IL (1) | IL251126A0 (enExample) |
| LT (1) | LT3105220T (enExample) |
| MX (2) | MX377801B (enExample) |
| NZ (1) | NZ724273A (enExample) |
| PL (1) | PL3105220T3 (enExample) |
| PT (1) | PT3105220T (enExample) |
| SA (1) | SA516371640B1 (enExample) |
| SG (2) | SG11201606667VA (enExample) |
| SI (1) | SI3105220T1 (enExample) |
| TW (2) | TWI666203B (enExample) |
| WO (1) | WO2015121397A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095727A1 (es) | 2013-03-27 | 2015-11-04 | Actelion Pharmaceuticals Ltd | Preparación de intermediarios de pirimidina |
| EP2907811A1 (en) * | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| CN105461638A (zh) * | 2015-12-10 | 2016-04-06 | 合肥久诺医药科技有限公司 | 一种马西替坦晶型及其制备方法 |
| CN105461639B (zh) * | 2015-12-10 | 2018-03-09 | 合肥久诺医药科技有限公司 | 一种高纯度马西替坦的精制方法 |
| JP7223701B2 (ja) * | 2017-02-27 | 2023-02-16 | イドーシア ファーマシューティカルズ リミテッド | ４－ピリミジンスルファミド誘導体の、エンドセリン関連疾患治療用の有効成分との合剤 |
| MA51203A (fr) | 2017-11-30 | 2020-10-07 | Idorsia Pharmaceuticals Ltd | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline |
| CN109232546B (zh) * | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
| CN114630668B (zh) * | 2019-11-07 | 2024-02-27 | 苏州科睿思制药有限公司 | 一种Aprocitentan晶型及其制备方法和用途 |
| WO2021237004A1 (en) * | 2020-05-21 | 2021-11-25 | Teva Pharmaceuticals International Gmbh | Solid state forms of aprocitentan and process for preparation thereof |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| WO2023111797A1 (en) * | 2021-12-17 | 2023-06-22 | Janssen Biotech, Inc. | Pyrimidine sulfamide derivatives and process for manufacturing them |
| EP4532472A1 (en) | 2022-05-25 | 2025-04-09 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| WO2025102245A1 (zh) * | 2023-11-14 | 2025-05-22 | 浙江天宇药业股份有限公司 | 一种双重内皮素受体拮抗剂阿普昔腾坦的合成方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048544A (zh) * | 1989-07-04 | 1991-01-16 | 赫彻斯特股份公司 | 2，4，6-三氟-1，3，5-三嗪的制备方法 |
| WO2002053557A1 (en) * | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| WO2003055863A1 (en) * | 2002-01-02 | 2003-07-10 | Actelion Pharmaceuticals Ltd | Novel alkansulfonamides as endothelin antagonists |
| WO2009024906A1 (en) * | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | 4-pyrimidinesulfamide derivative |
| CN103012279A (zh) * | 2012-11-27 | 2013-04-03 | 浙江工业大学 | 一种4，5，6-三氟嘧啶化合物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103716A2 (tr) * | 2001-12-25 | 2003-07-21 | Ba�Lama Al� | Zenginleştirilmiş dizel yakıt kompozisyonu |
| JP5667085B2 (ja) | 2009-02-13 | 2015-02-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ａｋｔインヒビターとしての融合されたピリミジン |
| US20110082151A1 (en) * | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| KR101471047B1 (ko) * | 2012-11-21 | 2014-12-08 | 주식회사 메디켐코리아 | 고순도 보센탄의 개선된 제조방법 |
| AR095727A1 (es) | 2013-03-27 | 2015-11-04 | Actelion Pharmaceuticals Ltd | Preparación de intermediarios de pirimidina |
| CN103724281A (zh) * | 2013-12-03 | 2014-04-16 | 镇江圣安医药有限公司 | N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用 |
| EP2907811A1 (en) | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
-
2014
- 2014-02-14 EP EP14155137.4A patent/EP2907811A1/en not_active Withdrawn
-
2015
- 2015-02-13 LT LTEP15706185.4T patent/LT3105220T/lt unknown
- 2015-02-13 CN CN201710130956.7A patent/CN107162988B/zh active Active
- 2015-02-13 EP EP17159638.0A patent/EP3214082B1/en active Active
- 2015-02-13 AR ARP150100449A patent/AR099434A1/es active IP Right Grant
- 2015-02-13 CN CN201580008410.3A patent/CN105992762B/zh active Active
- 2015-02-13 SI SI201531349T patent/SI3105220T1/sl unknown
- 2015-02-13 MX MX2017003134A patent/MX377801B/es unknown
- 2015-02-13 EA EA201691618A patent/EA032933B1/ru not_active IP Right Cessation
- 2015-02-13 BR BR112016018581-1A patent/BR112016018581B1/pt active IP Right Grant
- 2015-02-13 SG SG11201606667VA patent/SG11201606667VA/en unknown
- 2015-02-13 KR KR1020177006399A patent/KR102406358B1/ko active Active
- 2015-02-13 PL PL15706185T patent/PL3105220T3/pl unknown
- 2015-02-13 BR BR122017005939-4A patent/BR122017005939B1/pt active IP Right Grant
- 2015-02-13 EA EA201790343A patent/EA032460B1/ru not_active IP Right Cessation
- 2015-02-13 ES ES15706185T patent/ES2819504T3/es active Active
- 2015-02-13 AU AU2015217000A patent/AU2015217000B2/en active Active
- 2015-02-13 ES ES17159638T patent/ES2906458T3/es active Active
- 2015-02-13 EP EP15706185.4A patent/EP3105220B1/en active Active
- 2015-02-13 NZ NZ724273A patent/NZ724273A/en unknown
- 2015-02-13 TW TW106114126A patent/TWI666203B/zh not_active IP Right Cessation
- 2015-02-13 JP JP2016551796A patent/JP6431922B2/ja active Active
- 2015-02-13 SG SG10201701994RA patent/SG10201701994RA/en unknown
- 2015-02-13 HR HRP20201450TT patent/HRP20201450T1/hr unknown
- 2015-02-13 WO PCT/EP2015/053047 patent/WO2015121397A1/en not_active Ceased
- 2015-02-13 US US15/118,046 patent/US9938244B2/en active Active
- 2015-02-13 PT PT157061854T patent/PT3105220T/pt unknown
- 2015-02-13 TW TW104105167A patent/TWI663155B/zh active
- 2015-02-13 MX MX2016010486A patent/MX368014B/es active IP Right Grant
- 2015-02-13 KR KR1020167025089A patent/KR102261695B1/ko active Active
- 2015-02-13 HU HUE15706185A patent/HUE050974T2/hu unknown
- 2015-02-13 DK DK15706185.4T patent/DK3105220T3/da active
- 2015-02-13 CA CA2937277A patent/CA2937277C/en active Active
-
2016
- 2016-08-09 SA SA516371640A patent/SA516371640B1/ar unknown
- 2016-08-10 CL CL2016002008A patent/CL2016002008A1/es unknown
-
2017
- 2017-03-03 AR ARP170100539A patent/AR107801A2/es unknown
- 2017-03-03 CL CL2017000505A patent/CL2017000505A1/es unknown
- 2017-03-09 JP JP2017044868A patent/JP6421209B2/ja active Active
- 2017-03-13 IL IL251126A patent/IL251126A0/en active IP Right Grant
- 2017-04-12 AU AU2017202446A patent/AU2017202446B2/en not_active Ceased
-
2018
- 2018-02-27 HK HK18102771.1A patent/HK1243405A1/en unknown
-
2020
- 2020-09-04 CY CY20201100833T patent/CY1123319T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048544A (zh) * | 1989-07-04 | 1991-01-16 | 赫彻斯特股份公司 | 2，4，6-三氟-1，3，5-三嗪的制备方法 |
| WO2002053557A1 (en) * | 2000-12-18 | 2002-07-11 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| WO2003055863A1 (en) * | 2002-01-02 | 2003-07-10 | Actelion Pharmaceuticals Ltd | Novel alkansulfonamides as endothelin antagonists |
| WO2009024906A1 (en) * | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | 4-pyrimidinesulfamide derivative |
| CN103012279A (zh) * | 2012-11-27 | 2013-04-03 | 浙江工业大学 | 一种4，5，6-三氟嘧啶化合物的制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| Ionic liquids as media for nucleophilic fluorination;Murray, Christopher B.等;《Journal of Fluorine Chemistry》;20031231;第123卷(第1期);81-84 * |
| Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist;M. Iglarz et al;《The Journal of Pharmacology and Experimental Therapeutics》;20081231;第327卷(第3期);736-745 * |
| Process for preparing N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl)-N’-propylsulfamide and intermediates thereof;Anon.;《IP.com Journal》;20140121;第14卷(第2A期);实施例7、9 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105992762B (zh) | 制造嘧啶磺酰胺衍生物的方法 | |
| JP3662761B2 (ja) | フェノキシアルキルハライド誘導体の新規製造法 | |
| JP2015509907A (ja) | フッ素化物の単離方法 | |
| TWI643848B (zh) | 製備嘧啶中間物之方法 | |
| CN105294573B (zh) | 一种合成4,6-二氯-2-(丙硫基)-5-氨基嘧啶的方法 | |
| EP3257841B1 (en) | Synthesis process for chiral cyclopropyl ethynyl tertiary alcohol compound | |
| CN116143713B (zh) | 1,4-二氮杂环庚烷系列衍生物及其制备方法 | |
| CN102372533A (zh) | 酒石酸衍生物催化端炔锌试剂对含氟烷基芳酮的不对称加成方法 | |
| NZ729685B2 (en) | Process for manufacturing pyrimidine sulfamide derivatives | |
| CN111909040A (zh) | 一种Elagolix中间体2-氟-6-三氟甲基苄胺的制备方法 | |
| ITMI20011162A1 (it) | Alogenoarilsolfonammidi aventi caratteristiche antitumorali | |
| MX2008006378A (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20171010 Address after: Swiss A Skei Weil Applicant after: Aidu West Pharmaceutical Co. Ltd. Address before: Swiss A Skei Weil Applicant before: Actelion Pharmaceuticals Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |